Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma

References

• Global Initiative for AsthmaGlobal strategy for asthma management and prevention Available from: http://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/Accessed April 5, 2018
   Google Scholar
• SvedsaterHRobertsJPatelCMaceyJHiltonEBradshawLLife impact and treatment preferences of individuals with asthma and chronic obstructive pulmonary disease: results from qualitative interviews and focus groupsAdv Ther20173461466148128536998
   PubMed Web of Science ®Google Scholar
• McLaurinKKPokrsywinskiRO’QuinnSXuXHareendranAConceptualization of symptoms and symptom impacts among adults with inadequately controlled moderate-severe asthmaAm J Respir Crit Care Med2012185A1086
   Google Scholar
• ChippsBEHaselkornTPaknisBMore than a decade follow-up in patients with severe or difficult-to-treat asthma: The epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) IIJ Allergy Clin Immunol201814151590159728797732
   PubMed Web of Science ®Google Scholar
• JuniperEFGuyattGHEpsteinRSFerriePJJaeschkeRHillerTKEvaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trialsThorax199247276831549827
   PubMed Web of Science ®Google Scholar
• NelsenLMKimelMMurrayLTQualitative evaluation of the St George’s respiratory questionnaire in patients with severe asthmaRespir Med2017126323828427547
   PubMed Web of Science ®Google Scholar
• Fasenra™ (benralizumab) prescribing information Available from: https://www.azpicentral.com/fasenra/fasenra_pi.pdf#page=1Accessed January 10, 2018
   Google Scholar
• Fasenra™ (benralizumab) summary of product characteristics Available from: http://ec.europa.eu/health/documents/community-register/2018/20180108139598/anx_139598_en.pdfAccessed March 13, 2018
   Google Scholar
• KolbeckRKozhichAKoikeMMEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity functionJ Allergy Clin Immunol201012561344135320513525
   PubMed Web of Science ®Google Scholar
• PhamTHDameraGNewboldPRanadeKReductions in eosinophil biomarkers by benralizumab in patients with asthmaRespir Med2016111212926775606
   PubMed Web of Science ®Google Scholar
• PavordIDEosinophilic phenotypes of airway diseaseAnn Am Thorac Soc201310SupplS143S14924313765
   PubMedGoogle Scholar
• PriceDWilsonAMChisholmAPredicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practiceJ Asthma Allergy2016911226793004
   PubMedGoogle Scholar
• TaliniDNovelliFBacciESputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational studyBMJ Open201551e005748
   PubMed Web of Science ®Google Scholar
• BleeckerERFitzGeraldJMChanezPEfficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialThe Lancet20163881005621152127
   PubMed Web of Science ®Google Scholar
• FitzGeraldJMBleeckerERNairPBenralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet20163881005621282141
   PubMed Web of Science ®Google Scholar
• FitzGeraldJMBleeckerERMenzies-GowAPredictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studiesLancet Respir Med201861516428919200
   PubMed Web of Science ®Google Scholar
• GoldmanMHirschIZangrilliJGNewboldPXuXThe association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studiesCurr Med Res Opin20173391605161328644104
   PubMed Web of Science ®Google Scholar
• FowlerSJTavernierGNivenRHigh blood eosinophil counts predict sputum eosinophilia in patients with severe asthmaJ Allergy Clin Immunol2015135382282425445828
   PubMed Web of Science ®Google Scholar
• HastieATMooreWCLiHBiomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjectsJ Allergy Clin Immunol20131321728023706399
   PubMed Web of Science ®Google Scholar
• WagenerAHde NijsSBLutterRExternal validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthmaThorax201570211512025422384
   PubMed Web of Science ®Google Scholar
• XuXO’QuinnSHirschIGopalanGAsthma symptom improvements with benralizumab are associated with improvements in activity functions and health-related quality of life for patients with severe, uncontrolled asthma: results of pooled phase III benralizumab studiesAm J Respir Crit Care Med2017A4682
   Web of Science ®Google Scholar
• ChuppGLBradfordESAlbersFCEfficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trialLancet Respir Med20175539040028395936
   PubMed Web of Science ®Google Scholar
• CastroMZangrilliJWechslerMEReslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trialsLancet Respir Med20153535536625736990
   PubMed Web of Science ®Google Scholar
• DutileSKaptchukTJWechslerMEThe placebo effect in asthmaCurr Allergy Asthma Rep201414845624951239
   PubMed Web of Science ®Google Scholar
• CastroMRubinASLavioletteMEffectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trialAm J Respir Crit Care Med2010181211612419815809
   PubMed Web of Science ®Google Scholar
• WechslerMEKelleyJMBoydIOActive albuterol or placebo, sham acupuncture, or no intervention in asthmaN Engl J Med2011365211912621751905
   PubMed Web of Science ®Google Scholar